Trials / Completed
CompletedNCT03164785
Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease
Efficacy and Safety of Jinshuibao Capsule as Add-on Therapy to Angiotensin II Receptor Blockers on Diabetic Kidney Disease in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- Second Xiangya Hospital of Central South University · Academic / Other
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the therapeutic effect and safety of Jinshuibao Capsule on diabetic kidney disease in T2DM patients.
Detailed description
Diabetic Kidney Disease (DKD) is one of the most important microvascular complications of diabetes and is the leading cause of end-stage renal disease. Intensive glycemic and blood pressure control, combined with renin - angiotensin system blocking therapy (including ACEI and ARB drugs), has to a certain extent, delayed the progression of DKD, but still cannot completely block its development. Cordyceps sinensis is a traditional Chinese medicine and Jinshuibao Capsule is its artificial preparation, with the effect of renoprotection. However, its clinical application in diabetic kidney disease is not well-defined so far. The aim of this study is to investigate the potential use of Jinshuibao Capsule on microalbuminuria in T2DM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jinshuibao Capsule | 1.98g t.i.d. p.o. for 6 months |
Timeline
- Start date
- 2017-07-24
- Primary completion
- 2020-09-26
- Completion
- 2022-12-08
- First posted
- 2017-05-24
- Last updated
- 2024-01-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03164785. Inclusion in this directory is not an endorsement.